Market revenue in 2021 | USD 5,269.5 million |
Market revenue in 2030 | USD 25,726.3 million |
Growth rate | 19.3% (CAGR from 2021 to 2030) |
Largest segment | Recombinant non-glycosylated proteins |
Fastest growing segment | Recombinant Glycosylated Proteins |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilar contract manufacturing market will help companies and investors design strategic landscapes.
recombinant non-glycosylated proteins was the largest segment with a revenue share of 55.18% in 2021. Horizon Databook has segmented the Global biosimilar contract manufacturing market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global biosimilar contract manufacturing market , including forecasts for subscribers. This global databook contains high-level insights into Global biosimilar contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account